Investors and pharmaceutical companies are increasingly turning their attention to the China Biologics Market as a prime hub for growth. The confluence of a massive aging population and rising middle-class healthcare expenditure is creating a sustainable demand for high-end biological therapeutics. The government’s focus on encouraging innovation over imitation is shifting the ecosystem...